We are live on ! Find out more
STAB

Statera Biopharma

Delisted

STAB was delisted on the 11th of January, 2023.

4 hedge funds and large institutions have $3.29K invested in Statera Biopharma in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

4.52% less ownership

Funds ownership: 4.52% → 0% (-4.5%)

86% less funds holding

Funds holding: 29 → 4 (-25)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $184K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 25

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-25
Holders Change %
-86.21%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
25
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

STAB Hedge Fund Activity: Q1 2023 in Review

4 of the 6,290 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma (STAB) for Q1 2023, worth a combined $3.29K — down 98% from $200K a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of STAB and 0 opened new positions — a net loss of 25 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Renaissance Technologies, exiting entirely with an estimated $59K sold.

  • 4 institutional investors held Statera Biopharma (STAB) as of Q1 2023, down from 29 in Q4 2022.
  • Funds reported $3.29K of Statera Biopharma stock for Q1 2023, down 98% quarter-over-quarter.
  • 0 funds opened new Statera Biopharma positions in Q1 2023 and 25 closed out, a net change of -25 holders.
  • The largest Statera Biopharma seller in Q1 2023 was Renaissance Technologies, an estimated $59K sold.

Based on aggregated 13F filings for Q1 2023.